Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours

NCT06833008 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT06833008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06833008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours
Lead sponsor
Ipsen
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 14, 2025
Completion date
April 4, 2028
Enrollment
42 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor